TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01904864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elemental iron (NovaFerrum®)
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elemental iron (Ferrous Sulfate)
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
Study: NCT01737957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-fluence PRP with 532nm green LASER
Description: To administer low-fluence PRP in a single session for PDR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full-Fluence PRP with 532nm LASER
Description: To administer full-fluence PRP in two sessions for PDR
Study: NCT00111748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade, Thalidomide, Dexamethasone
Description: Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade, Thalidomide, Dexamethasone
Description: Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit.
Study: NCT02187913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
Study: NCT01953497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: URC102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00772785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
Study: NCT00331344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study: NCT01968733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT00331344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study: NCT00121654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation
Description: Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
Study: NCT01490502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
Study: NCT01774747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-1053
Description: DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DSP-1053
Description: DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Study: NCT03168295

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg then Placebo Oral Tablet
Description: SGLT2 inhibitor - Dapagliflozin then Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg then Placebo Oral Tablet
Description: SGLT2 inhibitor - Dapagliflozin then Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg then Placebo Oral Tablet
Description: SGLT2 inhibitor - Dapagliflozin then Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet then Dapagliflozin 10mg
Description: Placebo then SGLT2 inhibitor - Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet then Dapagliflozin 10mg
Description: Placebo then SGLT2 inhibitor - Dapagliflozin
Study: NCT03704155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion.
Study: NCT03850652

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic (Synergy-1) + Iron supplement
Description: In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
Study: NCT03850652

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Maltodextrin) + Iron Supplement
Description: participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
Study: NCT00121654

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal cord stimulation
Description: Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
Study: NCT03069079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene advice, non surgical periodontal treatment
Description: For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
Study: NCT01873859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
Study: NCT04082962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
Study: NCT03043079

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity
Description: Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity
Description: Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity
Description: Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
Study: NCT00491504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 sprays in each nostril
Study: NCT04820608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linking
Description: Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
Study: NCT04971057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia information program of renal biopsy
Description: Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
Study: NCT01518491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDOX Hydrogel
Description: NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAC Alone
Description: Patients will receive VAC therapy three time weekly for eight weeks
Study: NCT01214083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine + high-dose naltrexone (150 mg)
Description: All subjects will be evaluated weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (150 mg) alone
Description: All subjects will be evaluated weekly for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose naltrexone (50 mg) alone
Description: All subjects will be evaluated weekly for 12 weeks.
Study: NCT02942602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 g
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 2g
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study: NCT04395365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Trimoxazole 960Mg Dispersible Tablet
Description: Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT04043013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Taurus® (Rocky Mountain©) Brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Taurus® (Rocky Mountain©) Brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Taurus® (Rocky Mountain©) Brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Clip® SL3 High Torque (3M Unitek©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Clip® SL3 High Torque (3M Unitek©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Clip® SL3 High Torque (3M Unitek©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tip-Edge Plus® (TP Orthodontics©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tip-Edge Plus® (TP Orthodontics©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tip-Edge Plus® (TP Orthodontics©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Victory® (3M Unitek©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Victory® (3M Unitek©)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Victory® (3M Unitek©)
Study: NCT01811277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX sequential S-1
Description: 4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Study: NCT03416595

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N1115 Probiotic Supplement
Description: Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
Study: NCT03845946

Intervention type: BEHAVIORAL
Intervention: angioedema
Description: electronic tracking book

Intervention type: BEHAVIORAL
Intervention: angioedema
Description: electronic tracking book

Intervention type: BEHAVIORAL
Intervention: angioedema
Description: electronic tracking book

Intervention type: BEHAVIORAL
Intervention: angioedema
Description: electronic tracking book

Intervention type: BEHAVIORAL
Intervention: angioedema
Description: electronic tracking book
Study: NCT03109366

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online patient-provider communication service
Study: NCT01938950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Study: NCT02375308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HDT
Description: 20 sessions, individual psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACDT
Description: 20 sessions, individual psychotherapy
Study: NCT03006978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress
Study: NCT02888912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQUIA
Description: Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradia Direct Posterior
Description: The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
Study: NCT01938950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and Resistance Exercise
Study: NCT04299061

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire
Description: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs\*min\*days) + Mod (METs\*min\*days) + Vig (METs\*min\*days)~1. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Description: The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Awareness Questionnaire - prepared by the researchers
Description: It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perceived Stress Scale
Description: The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
Study: NCT02942602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.